Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Retraction Note: Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial

The Original Article was published on 31 March 2021

Retraction of: Scientific Reports https://doi.org/10.1038/s41598-021-85227-0, published online 31 March 2021


The Editors have retracted this Article.


After concerns were brought to the Editors' attention after publication, the raw data underlying the study were requested. The authors provided several versions of their dataset. Post-publication peer review confirmed that none of these versions fully recapitulates the results presented in the cohort background comparisons, casting doubt on the reliability of the data. Additional concerns were raised about the randomisation procedure, as the equal distribution of male and female patients is unlikely unless sex is a parameter considered during randomisation. However, based on the clarification provided by the authors, sex was not considered during this process. The Editors therefore no longer have confidence in the results and conclusions presented.


Hany M. Dabbous, Manal H. El-Sayed, Gihan El Assal, Hesham Elghazaly, Fatma F. S. Ebeid, Ahmed F. Sherief, Maha Elgaafary, Ehab Fawzy, Sahar M. Hassany, and Ahmed R. Riad disagree with the retraction. Mohamed A. TagelDin did not respond to the correspondence from the Editors about the retraction.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hany M. Dabbous.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Dabbous, H.M., El‑Sayed, M.H., El Assal, G. et al. Retraction Note: Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial. Sci Rep 11, 18983 (2021). https://doi.org/10.1038/s41598-021-98683-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41598-021-98683-5

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing